Canada

AbCellera

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database

Lead Product(s): LY-CoV555

Therapeutic Area: Infections and Infectious Diseases Product Name: LY3819253

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2020

Details:

The study will include up to 2,400 participants and assess the ability of LY-CoV555 to prevent infection of long-term care residents and facility staff who have been exposed to SARS-CoV-2, the virus that causes COVID-19.

Revive Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

Lead Product(s): Bucillamine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 31, 2020

Details:

The Phase 3 confirmatory clinical study is a multi-center, randomized, double-blind, placebo-controlled study of bucillamine in patients with mild-moderate COVID-19.

Altum Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Clinical Development Plan

Lead Product(s): Interferon a2b

Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: BetterLife Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition July 27, 2020

Details:

Altum reports that in May 2020 management requested a pre-IND meeting with the FDA with the intent to discuss the planned development of AP-003 (Interferon Alpha-2b for inhalation) for the treatment of COVID-19.

Altum Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum

Lead Product(s): AntiCovir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: BetterLife Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 11, 2020

Details:

BetterLife has amended terms of the agreement entered into on May 6, 2020 with Altum to acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AP-003, a potential COVID-19 treatment.

Altum Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum

Lead Product(s): AntiCovir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: BetterLife Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 04, 2020

Details:

BetterLife has secured lock-up agreements from shareholders of Altum Pharmaceuticals Inc. representing 67.12% of the outstanding common shares of Altum. BetterLife and Altum entered collaboration to to commercialize and sell AP-003 for COVID-19.

BetterLife Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Betterlife Pharma Announces Interferon Alpha-2b Covid-19 News Regarding its Emergence as a Potential Treatment for COVID-19

Lead Product(s): Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

The study investigated the use of interferon alpha-2b on 77 patients with moderate cases of COVID-19 and found that the interferon alpha-2b drug significantly accelerated clearance of the virus from the airways of patients.

BetterLife Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BetterLife Pharma Highlights Results from Recent Clinical Reports and Studies on use of Interferon

Lead Product(s): Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2020

Details:

Results from a recent trial suggests a significantly shorter time to viral clearance for patients treated with interferon alpha 2b (IFN?2b) compared to the group who received arbidol alone.

Altum Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BetterLife Pharma Enters into a Licensing Agreement with Altum Pharmaceuticals

Lead Product(s): AntiCovir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: BetterLife Pharma

Deal Size: $20.0 million Upfront Cash: $5.0 million

Deal Type: Licensing Agreement May 07, 2020

Details:

BetterLife Pharma has been worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AntiCovir, a COVID-19 treatment, from Altum Pharmaceuticals Inc.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

AbCellera

AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database

Revive Therapeutics

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

Altum Pharmaceuticals

BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Clinical Development Plan

Altum Pharmaceuticals

BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum

Altum Pharmaceuticals

BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum

BetterLife Pharma

Betterlife Pharma Announces Interferon Alpha-2b Covid-19 News Regarding its Emergence as a Potential Treatment for COVID-19

BetterLife Pharma

BetterLife Pharma Highlights Results from Recent Clinical Reports and Studies on use of Interferon

Altum Pharmaceuticals

BetterLife Pharma Enters into a Licensing Agreement with Altum Pharmaceuticals